As patients with ALK-positive NSCLC are identified and started on treatment, it is important that the advanced practitioner in oncology be aware of the benefits and risks associated with the newest ALK-active tyrosine kinase inhibitors. This evidence concerns the gene ALK and non-small cell lung carcinoma.